Barilli Amelia, Recchia Luciani Giulia, Visigalli Rossana, Sala Roberto, Soli Maurizio, Dall'Asta Valeria, Rotoli Bianca Maria
Laboratory of General Pathology, Department of Medicine and Surgery, University of Parma, 43125 Parma, Italy.
Immunohematology and Transfusion Medicine, University Hospital of Parma, 43125 Parma, Italy.
Biomedicines. 2023 Oct 3;11(10):2699. doi: 10.3390/biomedicines11102699.
In COVID-19, an uncontrolled inflammatory response might worsen lung damage, leading to acute respiratory distress syndrome (ARDS). Recent evidence points to the induction of inducible nitric oxide synthase (/iNOS) as a component of inflammatory response since is upregulated in critical COVID-19 patients. Here, we explore the mechanisms underlying the modulation of iNOS expression in human alveolar cells.
A549 WT and IRF1 KO cells were exposed to a conditioned medium of macrophages treated with SARS-CoV-2 spike S1. Additionally, the effect of IFNγ, IL-1β, IL-6, and TNFα, either alone or combined, was addressed. iNOS expression was assessed with RT-qPCR and Western blot. The effect of baricitinib and CAPE, inhibitors of JAK/STAT and NF-kB, respectively, was also investigated.
Treatment with a conditioned medium caused a marked induction of iNOS in A549 WT and a weak stimulation in IRF1 KO. IFNγ induced and synergistically cooperated with IL-1β and TNFα. The inhibitory pattern of baricitinb and CAPE indicates that cytokines activate both IRF1 and NF-κB through the JAK/STAT1 pathway.
Cytokines secreted by S1-activated macrophages markedly induce iNOS, whose expression is suppressed by baricitinib. Our findings sustain the therapeutic efficacy of this drug in COVID-19 since, besides limiting the cytokine storm, it also prevents induction.
在新型冠状病毒肺炎(COVID-19)中,不受控制的炎症反应可能会加重肺损伤,导致急性呼吸窘迫综合征(ARDS)。最近的证据表明,诱导型一氧化氮合酶(iNOS)的诱导是炎症反应的一个组成部分,因为在重症COVID-19患者中iNOS表达上调。在此,我们探讨人肺泡细胞中iNOS表达调控的潜在机制。
将A549野生型(WT)和干扰素调节因子1(IRF1)基因敲除(KO)细胞暴露于经严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突S1蛋白处理的巨噬细胞条件培养基中。此外,还研究了单独或联合使用干扰素γ(IFNγ)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)和肿瘤坏死因子α(TNFα)的作用。通过逆转录定量聚合酶链反应(RT-qPCR)和蛋白质免疫印迹法检测iNOS表达。还研究了巴瑞替尼(JAK/STAT抑制剂)和咖啡酸苯乙酯(CAPE,NF-κB抑制剂)的作用。
用条件培养基处理可导致A549 WT细胞中iNOS显著诱导,而在IRF1 KO细胞中刺激较弱。IFNγ诱导iNOS并与IL-1β和TNFα协同作用。巴瑞替尼和CAPE的抑制模式表明,细胞因子通过JAK/STAT1途径激活IRF1和NF-κB。
S1激活的巨噬细胞分泌的细胞因子显著诱导iNOS,其表达被巴瑞替尼抑制。我们的研究结果支持了这种药物在COVID-19中的治疗效果,因为它除了限制细胞因子风暴外,还能防止iNOS的诱导。